Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

Delayed Quote. Delayed  - 10/18 05:35:12 pm
43.5 GBp   +11.54%
10/18 REALM THERAPEUT : s) in Company
10/18 REALM THERAPEUT : Block Listing Application
10/16 REALM THERAPEUT : s) in Company
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector newsTweets

PuriCore plc : PuriCore Raises $3.5 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2012 | 09:11pm CEST
PuriCore plc ("PuriCore" or the "Company" or the "Group") PuriCore Raises $3.5 Million MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 January 2012 - PuriCore (LSE: PURI), the water- based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it closed on a new $3.5 million debt facility with Republic Bank on 29 December 2011. The debt will be utilized to finance the working capital requirements associated with Sterilox Fresh and FloraFresh System installations in H1 2012. The facility is structured as a promissory note with an imputed interest rate of 4%. Enquiries:

FTI Consulting Susan Quigley Ben Brewerton

+44 (0) 20 7831 3113

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REALM THERAPEUTICS PLC
10/18 REALM THERAPEUTICS : s) in Company
10/18 REALM THERAPEUTICS : Block Listing Application
10/16 REALM THERAPEUTICS : s) in Company
10/16 REALM THERAPEUTICS : Realm Therapeutics to speak at BIO Investor Forum
10/16 REALM THERAPEUTICS : to Present at the 2017 BIO Investor Forum
10/12 REALM THERAPEUTICS - REALM THERAPEUT : Completion of £19.3m Placing
10/12 REALM THERAPEUTICS : s) in Company
10/09 REALM THERAPEUTICS : Result of General Meeting
09/21 REALM THERAPEUTICS : Announces $26 Million PIPE Financing
09/21 REALM THERAPEUTICS : Proposed Placing to raise £19.3 million
More news
Financials ( GBP)
Sales 2017 0,72 M
EBIT 2017 -
Net income 2017 -
Finance 2017 4,70 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 57,2x
EV / Sales 2018 8,14x
Capitalization 45,7 M
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Mark Sampson Vice President-Research & Development
Christian Peters Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC15.00%60
INCYTE CORPORATION14.00%24 360
QUINTILES IMS HOLDINGS INC31.30%21 440
CELLTRION, INC.--.--%20 806
LONZA GROUP64.29%19 850
ALNYLAM PHARMACEUTICALS, INC.228.53%10 889